SCHEMBL1390867

SCHEMBL1390867

CCOc1nc(NCc2ccc(C)o2)nc(Nc2ccc3[nH]c(=O)c(=O)[nH]c3c2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ HPGD P15428 1/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ LMNA P02545 4/20 0.39
▸ THRB P10828 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ POLB P06746 2/20 0.39
▸ ESR2 Q92731 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ PDE4B Q07343 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ CA1 P00915 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1391296 0.85 MAPT (0.64) MAPTMEN1KMT2AMAPK1NPSR1
SCHEMBL1392295 0.83 MAPT (0.46) MAPTMEN1KMT2AMAPK1NPSR1
SCHEMBL1392125 0.83 MEN1 (0.42) MAPTMEN1KMT2AMAPK1NPSR1
SCHEMBL1391348 0.81 IP6K1 (0.43) MAPTMEN1KMT2AMAPK1NPSR1
SCHEMBL1391966 0.80 MAPT (0.50) MAPTMEN1KMT2AMAPK1LMNA
SCHEMBL1391372 0.79 MAPT (0.53) MAPTMEN1KMT2AMAPK1NPSR1
SCHEMBL1391379 0.79 MAPT (0.64) MAPTMEN1KMT2AMAPK1NPSR1
SCHEMBL1392662 0.79 POLB (0.51) MAPTMEN1KMT2ANPSR1ALDH1A1
SCHEMBL10282840 0.78 POLB (0.52) MAPTMEN1KMT2ANPSR1HPGD
SCHEMBL1391075 0.77 MAPT (0.45) MAPTMEN1KMT2AMAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 — — US disclosed
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 — — US disclosed
EP-2231624-A2 TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF Progenics Pharmaceuticals, Inc. (US) 2010-09-29 — — EP disclosed
WO-2009091388-A2 TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF PROGENICS PHARMACEUTICALS, INC. (US) 2009-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof HAVCR2, ZC3HAV1, MAVS MAPT 3654/4885MEN1 4840/4885KMT2A 4066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback